Browsing Tag
Nasdaq: GLMD
1 post
Galmed Pharmaceuticals (Nasdaq: GLMD) reports Q3 loss but refocuses on oncology with new Aramchol data and once-daily formulation
Galmed Pharmaceuticals shifts focus to oncology after reporting Q3 loss; Aramchol Meglumine’s new formulation shows promise for 2026 Phase 2 trials.